GENBGenerate Biomedicines, Inc.
$14.35
$14.35
$11.2152 weeks$20.40
GENB in its own filings
Nothing in GENB's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
6
Events found in the filings · across 53 filings · the record starts in 2026
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 26, 2026
Most recent filing · Form 8-K
- Record starts
- Mar 2, 2026
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Nov 5, 2026
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 7, 2026Generate Biomedicines, Inc.Earnings release · press release
- Mar 2, 2026As previously disclosed in the Registration Statement on Form S-1, as amended (File No. 333-293204) (the “Registration Statement”), of Generate Biomedicines, Inc. (the “Company”), and in connection with the completion of the initial public offering of the Company’s common stock (the “IPO”), the Company filed its …Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry